Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

Masamichi Mori, Naoki Kaneko, Yoko Ueno, +6

Investigational New Drugs

The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice

Masamichi Mori, Yoko Ueno, Satoshi Konagai, +12

Molecular Cancer Therapeutics

Eml4 GenesImmunologyCancer BiologyTumor BiologyAlk-driven Nsclc +14

Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist

Yasuharu Kimura, Ken-ichi Hatanaka, Yuki Naitou, +5

European Journal of Pharmacology

BiochemistryFunctional SelectivityMedicineMechanism Of ActionPharmacotherapy +3

Synthesis and Biological Evaluation of 3-Biphenyl-4-yl-4-phenyl-4<i>H</i>-1,2,4-triazoles as Novel Glycine Transporter 1 Inhibitors

Takashi Sugane, Takahiko Tobe, Wataru Hamaguchi, +15

Journal of Medicinal Chemistry

Pharmaceutical ScienceImmunologyPharmacotherapyChemical BiologyMolecular Pharmacology +14

Synthesis and structure–activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists

Itsuro Shimada, Kyoichi Maeno, Kenichi Kazuta, +7

Bioorganic & Medicinal Chemistry

Molecular PharmacologyMedicine5-Ht2c Receptor AgonistsMechanism Of ActionEthylamine Derivatives +4

Atropisomeric 4-Phenyl-4<i>H</i>-1,2,4-triazoles as Selective Glycine Transporter 1 Inhibitors

Takashi Sugane, Takahiko Tobe, Wataru Hamaguchi, +7

Journal of Medicinal Chemistry

ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML).

Masamichi Mori, Naoki Kaneko, Yoko Ueno, +6

Journal of Clinical Oncology

PharmacotherapyCancer BiologyTumor BiologyInternal Tandem DuplicationMyeloid Neoplasia +16

Discovery of &lt;i&gt;N&lt;/i&gt;-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-&lt;i&gt;N&lt;/i&gt;′-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor

Kazuhiko Iikubo, Yutaka Kondoh, Itsuro Shimada, +4

Chemical and Pharmaceutical Bulletin

Drug TargetChemoprevention StrategyPharmaceutical ChemistryAnaplastic Lymphoma KinaseTumor Biology +15

Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor -

Sadao Kuromitsu, Masamichi Mori, Itsuro Shimada, +12

Cancer Research

Cancer BiologyTumor BiologyAsp3026 Treated-miceReceptor Tyrosine KinaseCancer Cell Biology +17

ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in combination with cytarabine and anthracycline in acute myeloid leukemia (AML).

Yoko Ueno, Naoki Kaneko, Rika Saito, +4

Journal of Clinical Oncology

Oral Daily Asp2215ImmunologyAntitumor EfficacyPharmacotherapyTumor Biology +14